Cardiff Oncology Inc (CRDF) Company Profile & Statistics

Cardiff Oncology Inc
CRDF
(Nasdaq - US)
N/A
3.52
-0.96 (-21.43%)
in:usd•As of: May 03, 2024 15:59 UTC -4
After Market:3.59+0.07 (+1.99%)
Open
3.95
High
4.35
Low
3.12

About Cardiff Oncology Inc

CEO

Mark Erlander

Headquarters

11055 flintkote avenue

san diego, ca 92121, united states

Auditor

BDO USA, P.C.

Employees

Share Holders

Website

https://cardiffoncology.com

Industry

medical specialties

Sector

health technology

Company Overview

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.

Cardiff Oncology Inc Statistics

Valuation Measures

Market Capitalization ²	157.38M
Enterprise Value	138.72M
Enterprise Value/EBITDA (ttm)	-3.10
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	2.25
Price to Sales (ttm)	258.00
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-6594.92%
Profit Margin (ttm)	-7027.69%
Return on Equity (ttm)	-51.54%
Return on Invested Capital (ttm)	-55.21%
Return on Assets (ttm)	-45.11%

Income Statement

Revenue (ttm)	610.00K
Revenue Per Share (ttm)	0.01
Gross Profit (ttm)	610.00K
EBITDA (ttm)³	-44.80M
Net Income Avi to Common (ttm)	-40.25M
Diluted EPS (ttm)	-0.90

Share Statistics

Beta (5Y Monthly)	2.02
52-Week Change	87.23%
S&P500 52-Week Change	26.43%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	44.72M
Dividend Yield	0.00%
Float ⁴	41.89M
% Held by Insiders	6.30%
% Held by Institutions	16.29%

Balance Sheet

Total Cash (mrq)	67.19M
Total Cash Per Share (mrq)	1.50
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	5.91%
Quick Ratio (mrq)	7.41%
Book Value Per Share (mrq)	1.36

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.17
Free Cash Flow (ytd)	-7.82M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Cardiff Oncology Inc

Trade With A Regulated Broker